A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Prior treatment

• History of any Neisseria infection, unexplained, recurrent infections, or infection requiring treatment with systemic antibiotics.
• Participants testing positive for COVID-19 prior to dosing.

Other illness

• History of any clinically important disease or disorder.
• Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention.
• History of congenital or acquired immunodeficiency or complement deficiency or an underlying condition that predisposes to infection.
• Evidence of hepatitis B infection (positive for HBsAg or positive for anti-HBcAb) or hepatitis C viral infection (HCV Abs or hepatitis C RNA positive) or HIV infection (positive for HIV type 1 or type 2 Abs).
• Any cardiac abnormalities.
• Known or suspected history of drug abuse, history of alcohol abuse or smoking.

Lab values

• Current or recurrent disease of clinical significance that could affect clinical assessments or clinical laboratory evaluations.

Other

• A CAP activity \< 60% at screening.

• Females must have a negative pregnancy test.
• Contraceptive use by males and females should be consistent with local regulations.
• Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.
• For optional Japanese participants only:
  • Participants must be of Japanese descent defined as: first generation (born to 2 Japanese parents and 4 Japanese grandparents).
  • Born in Japan, and not have lived outside Japan for more than 5 years.
  • Lifestyle, including diet, must not have significantly changed since leaving Japan.